优思弗辅助阿拓莫兰治疗婴儿胆汁淤积症的效果

Clinical effect of Yousifu-assisted atomolan in the treatment of infantile cholestasis

目的分析优思弗辅助阿拓莫兰对婴儿胆汁淤积症(IC)临床症状与肝功能的改善效果以及毒性和不良反应发生情况的影响。方法选取78例IC婴儿,按照入院ID采用随机数字表法均分为对照组和观察组,每组39例。除了针对原发病的治疗外,对照组给予优思弗和门冬氨酸钾镁治疗,观察组给予优思弗辅助阿拓莫兰治疗,疗程为14 d。分析2组患儿在治疗过程中的临床症状评分、临床治疗效果、肝功能指标[谷丙转氨酶(ALT)、总胆红素(TBIL)、直接胆红素(DBIL)、总胆汁酸(TBA)、γ-谷氨酰转移酶(γ-GGT)、谷草转氨酶(AST)和碱性磷酸酶(ALP)]、肝纤4项[透明质酸(HA)、层黏连蛋白(LN)、Ⅲ型前胶原(PCⅢ)及Ⅳ型胶原(cⅣ)]水平以及毒性和不良反应发生情况。结果治疗14 d后,观察组患儿的临床总有效率(89.74%)明显高于对照组(71.79%),P<0.05。治疗前,2组患儿的各项临床症状评分、肝功指标比较差异无统计学意义(P>0.05);治疗14 d后,2组患儿的各项临床症状评分均明显降低(P<0.05),且观察组的各项临床症状评分均明显低于对照组(P<0.05)。治疗7,14 d后,2组患儿的肝功指标ALT、ALP、AST、TBIL、DBIL、TBA和r-GGT水平均明显降低,且观察组的以上各项肝功指标水平均明显低于对照组(P<0.05)。治疗14 d后,2组患儿的LN水平比较差异无统计学意义(P>0.05);2组患儿的HA、PCⅢ及cⅣ水平均明显降低,且观察组的HA、PCⅢ和cⅣ水平低于对照组(P<0.05)。观察组患儿的毒性和不良反应发生率为12.82%,明显低于对照组的33.33%(P<0.05)。结论优思弗辅助阿拓莫兰治疗IC患儿的临床效果明显,可有效恢复肝功能,改善临床症状,且毒性和不良反应低。

Objective To analyze the effect of Yousifu-assisted atomolan on the clinical symptoms,liver function improvement and toxicity and adverse reactions of infantile cholestasis(IC).Methods 78 infants with IC were randomly divided into control group and observation group according to the random number table of admission ID,39 cases in each group.In addition to the treatment for the primary disease,the control group was given the treatment of Yousifu and magnesium asparate potassium,and the observation group was given Yisifu-assisted atomolan.The course of treatment was 14 d.The clinical symptom score,clinical treatment effect,liver function index[alanine aminotransferase(ALT),total bilirubin(TBIL),direct bilirubin(DBIL),total bile acid(TBA),γ-glutamyltransferase(γ-GGT),aspartate aminotransferase(AST),alkaline phosphatase(ALP)],4 items of liver fiber[hyaluronic acid(HA),laminin(LN),procollagenⅢ(PCⅢ)and collagenⅣ(cⅣ)]and toxicity and adverse reactions were analyzed.Results After 14 d of treatment,the total clinical effective rate of the observation group was 89.74%,which was significantly higher than that of the control group(71.79%)(P<0.05).Before treatment,there was no significant difference in clinical symptom scores and liver function indexes between the 2 groups(P>0.05).After 14 d of treatment,the clinical symptom scores of the 2 groups were significantly lower(P<0.05),However,the clinical symptom scores of the observation group were significantly lower than the control group(P<0.05).After 7 d and 14 d of treatment,the liver function indexes of ALT,ALP,AST,TBIL,DBIL,TBA and r-GGT were significantly lower in the 2 groups,the above indicators of liver function in the observation group were significantly lower in the control group(P<0.05).After 14 d of treatment,there was no significant difference in LN level between the 2 groups(P>0.05),while the levels of HA,PCⅢand cⅣin the 2 groups were significantly lower,the levels of HA,PCⅢand cⅣin the observation group were lower than those in the control group(P<0.05).The incidence of toxicity and adverse reactions in the observation group was 12.82%,which was significantly lower than that in the control group(33.33%)(P<0.05).Conclusion The clinical effect of Yousifu-assisted atomolan in the treatment of children with IC is obvious,it can effectively restore liver function,improve clinical symptoms,and shows low toxicity and adverse reactions.